G. Resplandy

445 total citations
18 papers, 373 citations indexed

About

G. Resplandy is a scholar working on Analytical Chemistry, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, G. Resplandy has authored 18 papers receiving a total of 373 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Analytical Chemistry, 8 papers in Cardiology and Cardiovascular Medicine and 5 papers in Pharmacology. Recurrent topics in G. Resplandy's work include Analytical Methods in Pharmaceuticals (12 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). G. Resplandy is often cited by papers focused on Analytical Methods in Pharmaceuticals (12 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). G. Resplandy collaborates with scholars based in France, United Kingdom and Spain. G. Resplandy's co-authors include Patrice Jaillon, Christian Funck‐Brentano, Christian Laveille, Roeline Jochemsen, Aitana Calvo, Antonio Portolés, Ignacio Martínez, Julia Critchley, Bernard Walther and A. R. Taylor and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, British Journal of Clinical Pharmacology and European Journal of Pharmaceutical Sciences.

In The Last Decade

G. Resplandy

18 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Resplandy France 10 223 63 50 47 35 18 373
JC Petrie United Kingdom 12 189 0.8× 45 0.7× 37 0.7× 66 1.4× 45 1.3× 28 373
Elizabeth L. Todd United States 11 73 0.3× 69 1.1× 75 1.5× 54 1.1× 29 0.8× 14 310
Kurt Püchler Germany 9 195 0.9× 35 0.6× 65 1.3× 21 0.4× 37 1.1× 16 354
W. Akpan United States 6 182 0.8× 83 1.3× 81 1.6× 50 1.1× 44 1.3× 9 384
E von Möllendorff United States 9 168 0.8× 72 1.1× 88 1.8× 43 0.9× 59 1.7× 12 430
T Douglas Cowart United States 7 108 0.5× 35 0.6× 107 2.1× 50 1.1× 42 1.2× 10 347
G. Kaiser Switzerland 14 104 0.5× 135 2.1× 64 1.3× 74 1.6× 61 1.7× 20 451
CP Quarterman United Kingdom 10 79 0.4× 123 2.0× 81 1.6× 72 1.5× 24 0.7× 13 326
HJ Gomez United States 8 273 1.2× 79 1.3× 50 1.0× 56 1.2× 142 4.1× 9 494
G Hitzenberger Austria 9 80 0.4× 23 0.4× 51 1.0× 65 1.4× 79 2.3× 53 340

Countries citing papers authored by G. Resplandy

Since Specialization
Citations

This map shows the geographic impact of G. Resplandy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Resplandy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Resplandy more than expected).

Fields of papers citing papers by G. Resplandy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Resplandy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Resplandy. The network helps show where G. Resplandy may publish in the future.

Co-authorship network of co-authors of G. Resplandy

This figure shows the co-authorship network connecting the top 25 collaborators of G. Resplandy. A scholar is included among the top collaborators of G. Resplandy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Resplandy. G. Resplandy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Portolés, Antonio, et al.. (2006). Effects of Hypericum perforatum on Ivabradine Pharmacokinetics in Healthy Volunteers: An Open‐Label, Pharmacokinetic Interaction Clinical Trial. The Journal of Clinical Pharmacology. 46(10). 1188–1194. 43 indexed citations
3.
Aarons, Leon, et al.. (2005). The pharmacokinetics of perindoprilat in normal volunteers and patients: Influence of age and disease state. European Journal of Pharmaceutical Sciences. 26(1). 104–113. 4 indexed citations
4.
Laveille, Christian, et al.. (1998). Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers*. Clinical Pharmacology & Therapeutics. 64(2). 192–203. 116 indexed citations
5.
Jackson, Philip J., et al.. (1996). Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica. 26(2). 221–228. 29 indexed citations
6.
Critchley, Julia, Brian Tomlinson, & G. Resplandy. (1995). Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers.. British Journal of Clinical Pharmacology. 39(4). 361–368. 15 indexed citations
7.
Vandenburg, M. J., et al.. (1993). Digoxin Pharmacokinetics and Perindopril in Heart Failure Patients. The Journal of Clinical Pharmacology. 33(2). 146–149. 4 indexed citations
8.
Resplandy, G., et al.. (1993). The effect of haemodialysis on the pharmacokinetics of perindoprilat after long-term perindopril. European Journal of Clinical Pharmacology. 44(2). 183–187. 9 indexed citations
9.
Funck‐Brentano, Christian, et al.. (1992). The pharmacokinetics of perindopril in patients with liver cirrhosis.. British Journal of Clinical Pharmacology. 33(3). 326–328. 30 indexed citations
10.
Sennesael, J., Atif Ali, M. J. Vandenburg, et al.. (1992). The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.. British Journal of Clinical Pharmacology. 33(1). 93–99. 26 indexed citations
11.
Brée, Françoise, et al.. (1992). Specific and high affinity binding of perindoprilat, but not of perindopril to blood ACE.. PubMed. 30(9). 325–30. 6 indexed citations
12.
Resplandy, G., et al.. (1991). Pharmacokinetics of Perindopril in High-Risk Populations. Journal of Cardiovascular Pharmacology. 18(7). S9–18. 8 indexed citations
13.
14.
Resplandy, G., et al.. (1991). Pharmacokinetics of Perindopril in High-Risk Populations. Journal of Cardiovascular Pharmacology. 18. S9–18. 3 indexed citations
15.
Tod, M., et al.. (1990). Comparison of serum hydroquinidine determination by fluorescence polarization immunoassay and liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis. 8(3). 279–282. 3 indexed citations
16.
Grislain, L., et al.. (1990). Interspecies comparison of the metabolic pathways of perindopril, a new angiotensin-converting enzyme (ACE) inhibitor. Xenobiotica. 20(8). 787–800. 14 indexed citations
17.
Flouvat, B, et al.. (1988). [Dihydroquinidine metabolites after the administration in man of a delayed-action preparation].. PubMed. 43(4). 255–61. 4 indexed citations
18.
Resplandy, G., et al.. (1988). Specific Determination of Hydroquinidine and Its Major Metabolites in Biological Fluids by High Performance Liquid Chromatography. Journal of Liquid Chromatography. 11(7). 1495–1511. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by JC Petrie Breakdown of academic impact, for papers by Elizabeth L. Todd Breakdown of academic impact, for papers by Kurt Püchler Breakdown of academic impact, for papers by W. Akpan Breakdown of academic impact, for papers by E von Möllendorff Breakdown of academic impact, for papers by T Douglas Cowart Breakdown of academic impact, for papers by G. Kaiser Breakdown of academic impact, for papers by CP Quarterman Breakdown of academic impact, for papers by HJ Gomez Breakdown of academic impact, for papers by G Hitzenberger
Rankless by CCL
2026